World Top 50 Stem Cell Influencers
Chris Mason MD, PhD, FRCS #3
Chris Mason is Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies. He has a multidisciplinary track record spanning discovery, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business. He holds a Clinical Sciences degree from Imperial College London, an MD from the United Medical & Dental Schools of Guy’s & St. Thomas’s Hospitals (now King’s College London) and a PhD in tissue-engineering bioprocessing from University College London. Chris specialized in surgery and is a Fellow of the Royal College of Surgeons both of England and in Ireland. Current appointments include; Chair of the BioIndustry Association (BIA) Regenerative Medicine & Cell Therapy Advisory Committee, Senior Editor of "Regenerative Medicine" journal, Co-founder and CEO of the London Regenerative Medicine Network, Trustee of the UK Stem Cell Foundation and of the British Neurological Research Trust and Co-Chair of the Alliance for Regenerative Medicine Cell Therapy Section. He sits on a number of national funding committees including BIRAX (Britain-Israel Research and Academic Exchange Partnership), Canada Foundation for Innovation (CFI) and Networks of Centres of Excellence of Canada (NCE).
Chris is on many national and international committees, working groups and initiatives related to the academic, clinical and commercial advancement of cell therapy including; Regenerative Medicine Expert Group (UK government policy advisory group), UK-Israel Science Council, International Expert Advisory Panel of the Canadian Stem Cell Foundation, ISSCR Industry Committee, ARM Communication & Education and Science & Technology Committees, ISCT Commercialization Committee, and United States Pharmacopeia (USP) Monographs - Biologics & Biotechnology Expert Committee. He is on the Advisory Panel of the Cell Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) and also advises a number of industry organisations including big pharma. Chris is a general spokesperson for the sector including frequent newspaper, radio and TV interviews plus social media via Twitter @Prof_ChrisMason.
Gregory A. BonfiglioGregory A. Bonfiglio #14
Founder & Managing Partner Proteus, LLC
Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC. Mr. Bonfiglio was an early investor in the field of stems cell & regenerative medicine, and he continues to actively invest in the field. Proteus is raising a new early stage, venture fund focused exclusively on regenerative medicines.
Mr. Bonfiglio is the Chairman of the Board of the Centre for Commercialization of Regenerative Medicine, a RM Translation Center in Toronto, Canada. He is a Member of the ISSCR and is on their Advisory Board, as well as their Finance Committee. He also is a Member of the ISCT.
Mr. Bonfiglio has served on the Boards of several RM companies, including VistaGen Therapeutics (in vitro tools from hESCs); California Stem Cell (hESC tools & therapeutics); and StemCyte, Inc. (cord blood storage & therapeutics). Mr. Bonfiglio is a frequent speaker at Regenerative Medicine Conferences. In 2013, Mr. Bonfiglio was listed among the Top 50 Stem Cell Influencers in the world (Ranked 14th).
From 2000 – 2005, Mr. Bonfiglio was a General Partner with Anthem Venture Partners – an early stage venture fund in California. Mr. Bonfiglio led Anthem’s investment in Advanced Cell Technology in 2000, and he helped take the Company public in 2005. Mr. Bonfiglio also led Anthem’s investment in Corus Pharma, and helped engineer the sale of Corus to Gilead.
Prior to joining Anthem, Mr. Bonfiglio was a Partner with Morrison & Foerster, where he worked extensively with technology clients. Mr. Bonfiglio was an Adjunct Professor of Law at Stanford Law School, from 1996 to 2000. He has been a Guest Lecturer at the Stanford Business School on the Commercialization of RM Technologies. From 1995 -2005, he was a regular Guest Lecturer at the UC Berkley Haas Business School in the Entrepreneurship Program.
Mr. Bonfiglio received his B.A. in Mathematics (magna cum laude) from Michigan State University in 1975, and his J.D. (magna cum laude) from the University of Michigan Law School in 1981.
Geoff MacKay #33
Geoff is a skilled Chief Executive with proven success leading highly innovative businesses. He has focused in the field of Regenerative Medicine for the last 15 years and is credited with building the first cell-based technology business model which has attained material commercial success as measured by revenue and profit.
Most recently, Geoff spent 11 years as C.E.O. of Organogenesis Inc. in Boston. This company has treated roughly 1 million patients with living cell-based therapies which constitutes more than the rest of the regulated world combined. Paramount to the success of the company was addressing the major hurdles faced in the field of cell-based regenerative medicine; cost-effective manufacturing, navigating regulators and payers, building a reliable supply chain and an effective commercial infrastructure. These learnings, developed and refined, are directly applicable to the broader field. In addition to financial success, relevant metrics include obtaining the first FDA CBER approval for a mass-produced cell therapy and successfully implementing >50 FDA approved process changes to on-market products.
Geoff has a strong pharma heritage, having spent 11 years at Novartis where he held senior leadership positions within the Immunology franchise in Canada, USA and at the Global office in Basel Switzerland.
Geoff has broad international experience and contacts across pharma, biotech and device industries via leadership roles within the life science industry. Examples include: Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, Advisory Council to the Health Policy Commission for Massachusetts, Deans Advisory Council Western University School of Podiatric Surgery, and Chairman of Audit Committee of the Center for Commercialization of Regenerative Medicine (C.C.R.M.).
Anthony Atala #36
Institute for Regenerative Medicine, Wake Forest
Anthony Atala, M.D., is the Director of the Wake Forest Institute for Regenerative Medicine, and the W.H. Boyce Professor and Chair of the Department of Urology at Wake Forest University.